The first 2-3 years of life are crucial for shaping childhood health. Amid others, the importance of early-life gut microbiota in infant’s development and later human health has been long speculated. In particular, bifidobacteria are playing an essential role in infant’s gut microbiota and immune system maturation that supports its probiotic use in that age span.

A new randomized, double-blind and controlled multicenter clinical study has found that a synbiotic formula supplemented with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides and Bifidobacterium breve M-16V may modulate healthy toddlers’ gut microbiota by increasing levels of Bifidobacterium.